164 related articles for article (PubMed ID: 8836913)
21. [Pharmaceutical device of IFN].
Higuchi Y; Hashida M
Nihon Rinsho; 2006 Jul; 64(7):1374-9. PubMed ID: 16838659
[TBL] [Abstract][Full Text] [Related]
22. Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a.
Klein SB; Blatt LM; Taylor MW
J Interferon Res; 1993 Oct; 13(5):341-7. PubMed ID: 8301154
[TBL] [Abstract][Full Text] [Related]
23. Three-dimensional models of interferon-alpha subtypes IFN-con1, IFN-alpha8, andIFN-alpha1 derived from the crystal structure of IFN-alpha2b.
Walter MR
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-52-S9-62. PubMed ID: 9208873
[TBL] [Abstract][Full Text] [Related]
24. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses.
Tan H; Derrick J; Hong J; Sanda C; Grosse WM; Edenberg HJ; Taylor M; Seiwert S; Blatt LM
J Interferon Cytokine Res; 2005 Oct; 25(10):632-49. PubMed ID: 16241862
[TBL] [Abstract][Full Text] [Related]
25. Binding and activity of all human alpha interferon subtypes.
Lavoie TB; Kalie E; Crisafulli-Cabatu S; Abramovich R; DiGioia G; Moolchan K; Pestka S; Schreiber G
Cytokine; 2011 Nov; 56(2):282-9. PubMed ID: 21856167
[TBL] [Abstract][Full Text] [Related]
26. New and modified interferon alfas: preclinical and clinical data.
Masci P; Bukowski RM; Patten PA; Osborn BL; Borden EC
Curr Oncol Rep; 2003 Mar; 5(2):108-13. PubMed ID: 12583827
[TBL] [Abstract][Full Text] [Related]
27. Cloning, expression and antiviral activity of mink alpha-interferons.
Zhang HL; Zhao JJ; Chai XL; Zhang L; Bai X; Hu B; Liu H; Zhang DL; Ye M; Wu W; Yan XJ
BMC Vet Res; 2015 Feb; 11():42. PubMed ID: 25889984
[TBL] [Abstract][Full Text] [Related]
28. Human interferons alpha, beta and omega.
Bekisz J; Schmeisser H; Hernandez J; Goldman ND; Zoon KC
Growth Factors; 2004 Dec; 22(4):243-51. PubMed ID: 15621727
[TBL] [Abstract][Full Text] [Related]
29. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
[TBL] [Abstract][Full Text] [Related]
30. Wherefore interferon?
Gresser I
J Leukoc Biol; 1997 May; 61(5):567-74. PubMed ID: 9129205
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions.
Yanai Y; Sanou O; Kayano T; Ariyasu H; Yamamoto K; Yamauchi H; Ikegami H; Kurimoto M
J Interferon Cytokine Res; 2001 Oct; 21(10):835-41. PubMed ID: 11710996
[TBL] [Abstract][Full Text] [Related]
32. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
[TBL] [Abstract][Full Text] [Related]
33. Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells.
Schijns VE; Van der Neut R; Haagmans BL; Bar DR; Schellekens H; Horzinek MC
J Gen Virol; 1991 Apr; 72 ( Pt 4)():809-15. PubMed ID: 1849968
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha].
Wang H; Jia X; Yang L; Sun L; Wang H; Liu W
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1556-60. PubMed ID: 19160837
[TBL] [Abstract][Full Text] [Related]
35. Isolation of a biologically active soluble human interferon-alpha receptor-GST fusion protein expressed in Escherichia coli.
Nguyen NY; Sackett D; Hirata RD; Levy DE; Enterline JC; Bekisz JB; Hirata MH
J Interferon Cytokine Res; 1996 Oct; 16(10):835-44. PubMed ID: 8910769
[TBL] [Abstract][Full Text] [Related]
36. Comparative antiproliferative and receptor binding activities of interferons alpha and beta on lymphoblastoid and melanoma cells.
Hertzog PJ; Johns TG; Callister KA; Dinatale A; Linnane AW
Biochem Int; 1990 Dec; 22(6):1095-102. PubMed ID: 2151021
[TBL] [Abstract][Full Text] [Related]
37. Infergen (interferon alfacon-1).
Gastroenterol Nurs; 1998; 21(1):30-1. PubMed ID: 9555366
[No Abstract] [Full Text] [Related]
38. Different interactions of interferon-alpha subtypes at the surface of epithelial and lymphoid cells.
Overall ML; Chambers P; Hertzog PJ
J Interferon Res; 1992 Aug; 12(4):281-8. PubMed ID: 1431308
[TBL] [Abstract][Full Text] [Related]
39. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells.
Hagelstein J; Kist A; Stremmel W; Galle PR
Arzneimittelforschung; 1998 Mar; 48(3):343-7. PubMed ID: 9553691
[TBL] [Abstract][Full Text] [Related]
40. Biological activities and receptor binding of two human recombinant interferons and their hybrids.
Meister A; Uzé G; Mogensen KE; Gresser I; Tovey MG; Grütter M; Meyer F
J Gen Virol; 1986 Aug; 67 ( Pt 8)():1633-43. PubMed ID: 3016158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
